Citation: | KANG Zhenhua, CHEN Yuandong, XU Cheng, YOU Jian, QIN Minjian, QIN Yong. Optimization of pramipexole hydrochloride sustained-release tablets using Box-Behnken design and mechanism of in vitro drug release[J]. Journal of China Pharmaceutical University, 2015, 46(1): 66-72. DOI: 10.11665/j.issn.1000-5048.20150108 |
[1] |
Wang XN,Liu GD,Xiao Q,et al.Observation of curative effect of dopamine receptor antagonist pramipexole for treatment on non-motor symptoms of Parkinson′s disease[J].J Clin Neur(临床神经病学杂志),2010,23(4):299-301.
|
[2] |
Chwieduk CM,Curran MP.Pramipexole extended release[J].CNS drugs,2010,24(4):327-336.
|
[3] |
Thomas F.Preparation and use of pramipexole hydrochloride sustained-release tablets:CN,101005830B[P].2010-09-29[2014-06-09] .
|
[4] |
Wang XD,Liu K,LiQ K,et al.Optimized formulation of levofloxacin gastric floating tablet by Box-Behnken design[J].Chin J Mod Appl Pharm(中国现代应用药学),2013,30(4):406-411.
|
[5] |
Deepan T,Paulambethkar K,Vijayalakshmi R,et al.A validated RP-HPLC method for the estimation of pramipexole dihydrochloride in pH armaceutical dosage form[J].World J Chem,2012,7(2):59-63.
|
[6] |
Sekhar KS,Nagabhushanam MV,Rao KRSS,et al.Formulation development and in vivo evaluation of pramipexole dihydrochloride monohydrate extended release tablets for Parkinson′s disease[J].Der Pharm Lett J,2013,5(4):153-163.
|